The Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating
eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1
unselected population.
This is getting an oral presentation because of positive results.
Relatlimab got approval with a 25% increase in efficacy.
Earlier TACTI-002 results show eftilagimod doubled efficacy.
If updated results show this trend holds up we could see approval and sales within a year.
Ann: Immutep to announce new TACTI-002 data at ASCO 2022, page-15
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.045(13.2%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.0¢ | 29.5¢ | $1.468M | 4.740M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 37350 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 79295 | 3 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |